Drugs / PLM60
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03553914 | Jan 2021 → Jan 2024 | peripheral T-cell lymphoma, not otherwise specified | Conjupro Biotherapeutics, Inc. | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PLM60 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03553914 ↗ |
| Route | Intravenous | “administered via intravenous infusion” NCT03553914 ↗ |